Cargando…
Co-Administration of Simvastatin Does Not Potentiate the Benefit of Gene Therapy in the mdx Mouse Model for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is the most common and cureless muscle pediatric genetic disease, which is caused by the lack or the drastically reduced expression of dystrophin. Experimental therapeutic approaches for DMD have been mainly focused in recent years on attempts to restore the express...
Autores principales: | Bourg, Nathalie, Vu Hong, Ai, Lostal, William, Jaber, Abbass, Guerchet, Nicolas, Tanniou, Guillaume, Bordier, Fanny, Bertil-Froidevaux, Emilie, Georger, Christophe, Daniele, Nathalie, Richard, Isabelle, Israeli, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878028/ https://www.ncbi.nlm.nih.gov/pubmed/35216132 http://dx.doi.org/10.3390/ijms23042016 |
Ejemplares similares
-
Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy
por: Albini, Sonia, et al.
Publicado: (2023) -
Social stress is lethal in the mdx model of Duchenne muscular dystrophy
por: Razzoli, Maria, et al.
Publicado: (2020) -
Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in the dystrophic muscle in Duchenne muscular dystrophy
por: Vu Hong, Ai, et al.
Publicado: (2022) -
Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy
por: Whitehead, Nicholas P., et al.
Publicado: (2016) -
A revised model for mitochondrial dysfunction in Duchenne muscular dystrophy
por: Vu Hong, Ai, et al.
Publicado: (2021)